Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Heiduschka, G; Grah, A; Oberndorfer, F; Kadletz, L; Altorjai, G; Kornek, G; Wrba, F; Thurnher, D; Selzer, E.
Improved survival in HPV/p16-positive oropharyngeal cancer patients treated with postoperative radiotherapy.
Strahlenther Onkol. 2015; 191(3):209-216
Doi: 10.1007/s00066-014-0753-7
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Thurnher Dietmar
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- In the literature, HPV infection and/or p16 positivity have been consistently demonstrated to correlate with improved response rates in oropharyngeal squamous cell carcinoma (OPSCC) patients treated with primary radiotherapy (RT) alone and in combination with chemotherapy. However, the exact role of HPV/p16 positivity in patients treated with postoperative RT is still unclear. We analyzed tumor samples for HPV-DNA and p16 expression and correlated these variables with treatment outcome in a series of 63 consecutively treated oropharyngeal cancer patients (95% stage III/IV). HPV and p16 analysis were performed using validated test systems. Survival was estimated by the Kaplan-Meier method. Cox proportional hazard regression models were applied to compare the risk of death among patients stratified according to risk factors. Expression of p16 or high-risk HPV-DNA was detected in 60.3% and 39.6% of the tumors, respectively. p16 expression [overall survival (OS) at 2 years: 91%] as well as HPV infection (OS at 2 years: 95%) was associated with improved OS. Mean survival in p16-positive patients was 112 months compared to 64.6 months in case of p16 negativity. All HPV-positive tumors stained positive for p16. In a multivariable analysis, p16 positivity was associated with improved OS and with disease-free survival. p16 expression and HPV infection are strongly associated with the outcome of postoperatively irradiated OPSCC patients. HPV and p16 double-negative OPSCC patients should be regarded as a distinct "very high-risk patient group" that may benefit from intensified or novel treatment combinations.
- Find related publications in this database (using NLM MeSH Indexing)
- Adult -
- Aged -
- Carcinoma, Squamous Cell - mortality
- Carcinoma, Squamous Cell - pathology
- Carcinoma, Squamous Cell - radiotherapy
- Carcinoma, Squamous Cell - surgery
- Combined Modality Therapy -
- Female -
- Human papillomavirus 16 -
- Humans -
- Male -
- Middle Aged -
- Neoplasm Staging -
- Oropharyngeal Neoplasms - mortality
- Oropharyngeal Neoplasms - pathology
- Oropharyngeal Neoplasms - radiotherapy
- Oropharyngeal Neoplasms - surgery
- Oropharyngeal Neoplasms - virology
- Papillomavirus Infections - mortality
- Papillomavirus Infections - pathology
- Papillomavirus Infections - radiotherapy
- Papillomavirus Infections - surgery
- Papillomavirus Infections - virology
- Radiotherapy, Adjuvant -
- Survival Rate -
- Find related publications in this database (Keywords)
- Head and neck cancer
- Carcinoma, squamous cell
- Human papillomavirus
- Surgery
- Disease-free survival